抗胆固醇药物和痴呆风险:利用基于干细胞的研究来补充药理流行病学
Tiara A Schwarze-Taufiq1,2, Inez K A Pranoto1,2, Katherine Hui1,2
1Department of Laboratory Medicine and Pathology University of Washington Seattle Washington USA.
Alzheimer's & dementia (New York, N. Y.)
|February 6, 2025
概括
某些抗胆固醇 (AC) 药物,如抗抑郁药和膀抗肌肉药,具有神经毒性,并与痴呆风险有关. 这项研究使用了人类干细胞衍生的神经元来证实这些AC药物效应.
科学领域:
- 神经科学和药理学 神经科学和药理学
- 干细胞生物学 干细胞生物学
- 药物安全与毒理学
背景情况:
- 抗胆固醇 (AC) 药物被老年人广泛使用,尽管已知风险包括痴呆发病率增加.
- 以前的研究表明,特定的AC类 (抗抑郁药,膀抗肌肉药) 和痴呆症之间存在联系,但根据指示混是一个挑战.
- 人类诱导的多能干细胞衍生神经元 (hiPSC-Ns) 提供了一个直接评估AC药物神经毒性的模型,绕过混因素.
研究的目的:
- 研究各种抗胆固醇药物类别对与痴呆相关的表型的直接细胞效应.
- 为了确定特定的AC药物类是否表现出差异性神经毒性,使用人类iPSC衍生的神经元模型.
主要方法:
- 人类诱导多能干细胞 (hiPSC) 衍生的神经元被用八种不同类别的AC药物治疗:抗抑郁药,膀抗肌药,抗组胺药和抗药.
- 评估结果包括药物诱导的细胞毒性,条件介质中的粉样β (Aβ) 的水平,以及细胞内化.
- 选择度和治疗持续时间是为了模仿人类潜在的暴露水平.
主要成果:
- 抗抑郁药和膀抗糖药在hiPSC-Ns.中表现出一致的细胞毒性.
- 抗胰岛素和抗药在测试剂量和持续时间时没有显著的细胞毒性.
- 细胞毒性AC药物改变了粉样β (Aβ1-42) 水平,但没有观察到酸化/总比例的显著变化.
结论:
- 这些发现支持基于人口的研究,通过在细胞模型中证明它们的直接神经毒性作用,将某些AC类与痴呆风险联系起来.
- 这项研究表明,与AC药物类相关的痴呆症差异风险的分子基础.
- 未来的研究应该探索对来自不同受试者的hiPSC衍生细胞的影响,并调查其他神经生物学结果,如突触功能和神经炎症.
更多相关视频
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
9.8K
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
90
相关概念视频
01:22Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158
01:26Alzheimer's Disease: Overview
437
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
437
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
01:30Dementia
92
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
92